Castle Biosciences

NEXT MONTH: Castle's executive management will present a company overview at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, at 1:20pm ET. Details/registration: hubs.la/Q04gpsXd0

This calls for a celebration!🎉 Castle's AdvanceAD-Tx test has won the Genomics Innovation Award in the 10th annual MedTech Breakthrough Awards program, which recognizes companies driving meaningful progress and improving patient care across the global health and medical technology industry. This marks the fifth MedTech Breakthrough Award that Castle has earned for our innovative testing solutions. AdvanceAD-Tx is Castle's clinically validated gene expression profile (GEP) test designed to guide systemic treatment decision making in patients 12 and older with moderate-to-severe atopic dermatitis (AD). Further details: hubs.la/Q04gd2XT0

Gene Expression Profiling (GEP) is a laboratory testing method that measures which genes are being expressed in a cell at any given moment. Understanding the expression levels of certain genes for a specific type of cancer helps to create a molecular portrait of the cancer. This information can provide a deeper understanding of the biology of a tumor, which can vary from patient to patient, and can be utilized in several ways: to diagnose a disease or condition, to understand response to therapy, or to provide prognostic information, all of which can guide clinical management decisions. #GEP #GeneExpressionProfiling #SkinCancerAwarenessMonth #DecisionDxMelanoma #DecisionDxSCC #MyPathMelanoma #DecisionDxUM

We would walk forever for a cure! 💙#TeamCastle was proud to support AIM at Melanoma's 20th annual Steps Against Melanoma walk in Galveston, Texas, helping to raise awareness, fund research, and support patients and caregivers every step of the way. #SkinCancerAwarenessMonth Representing #TeamCastle: Camilla Zuckero, Olga Cain, and Carmen Gomez

JUST RELEASED: Castle Biosciences announces financial results for the 1st quarter ended 3/31/26 Q1 2026 Highlights: Revenue of $83.7 million; Q1 2026 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 36% over Q1 2025; raising full-year 2026 revenue guidance to $345-355 million from $340-350 million, as of 3/31/26 View further results and access the webcast archive here: hubs.la/Q04fKL_20

JOIN US TODAY: Castle will release Q1 2026 financial results via webcast at 4:30 pm ET. Registration/log-in details: hubs.la/Q04c9CmS0

In honor of #SkinCancerAwarenessMonth, Castle continues longstanding collaborations with AIM at Melanoma, the Melanoma Research Foundation, The Skin Cancer Foundation, IMPACT Melanoma, and The Sun Bus to advance awareness and education through several community initiatives, including advocacy walks, skin cancer screenings, and patient education programs nationwide. Press release: hubs.la/Q04fvnpq0

NEW DATA generated by researchers at Mayo Clinic will be presented at Digestive Disease Week® #DDW2026, taking place May 2–5 in Chicago. The findings, featured in two poster presentations, demonstrate how molecular risk stratification with the TissueCypher test can refine risk assessment and directly inform real-world management decisions for patients with Barrett's esophagus. "The findings presented at DDW 2026 suggest that relying on traditional clinical risk assessment alone may not fully capture a patient's true risk of progression," said Cadman L. Leggett, M.D., gastroenterologist at Mayo Clinic and senior author on both studies. "Molecular risk stratification with TissueCypher can provide more clinically actionable insights by more accurately identifying which patients are truly at higher or lower risk. And we see that translating into real-world changes in how physicians manage patients." Details: hubs.la/Q04flcxq0

Great to spend time at #DDW2026 with organizations working to advance early detection in esophageal cancer. Appreciate the shared commitment to prevention and better patient outcomes. @CastleBio @TissueCypher

An all-new supplement from @CastleBio explores innovations in precision medicine for #melanoma. digitaleditions.walsworth.com/publication/?i…

For over a decade, @CastleBio and #IMPACTMelanoma have partnered for real impact raising awareness and saving lives. Learn more: bit.ly/3vvAMCn #PartnersInPrevention #IMPACTMelanoma

#BarrettsEsophagus (BE) is a precursor to esophageal cancer, but not all BE risk is the same. Different people with the same type of BE may have varying levels of cancer risk. If you have BE, it is important to determine your individual risk of developing esophageal cancer so that your healthcare professional creates a care plan specific to your needs. Learn more about #TissueCypher, a specialized test that analyzes BE tissue to predict an individual's risk of future progression to cancer: hubs.la/Q049j1bD0 #EsophagealCancerAwarenessMonth

An all-new TDD Supplement from @CastleBio explores innovations in precision medicine for #melanoma. digitaleditions.walsworth.com/publication/?i…

Castle will present NEW DATA on the DecisionDx-Melanoma test addressing a critical clinical challenge in melanoma care: identifying which patients with early-stage disease are at risk for poor outcomes and may benefit from intensified management. The data, which will be presented at the 22nd European Congress of Dermato-Oncology (EADO) Congress and the American College of Mohs Surgery (ACMS) 58th Annual Meeting, further demonstrate that DecisionDx-Melanoma provides clinically actionable, personalized information that refines risk assessment across patients with cutaneous melanoma. Highlights/details: hubs.la/Q04cYGfR0

🔬🧬🧪 Happy #LabWeek2026! We are celebrating our super-talented laboratory professionals. THANK YOU for all you do in advancing Castle's innovative tests that provide personalized information to guide patient care and improve health outcomes! #MLPW26 #SkinCancer #Melanoma #UvealMelanoma #BarrettsEsophagus #AtopicDermatitis #CastleCulture #DecisionDxMelanoma #DecisionDxSCC #MyPathMelanoma #DecisionDxUM #TissueCypher #AdvanceADTx

Advancing precision medicine in atopic dermatitis (AD) starts with understanding the biology behind each patient’s disease. In this recent @DermTimesNow article, Dr. Aaron Farberg highlights how AdvanceAD-Tx, a 487-gene expression profile (GEP) test, can help guide systemic treatment decisions, enabling clinicians to better match therapies to individual patients and reduce trial-and-error approaches. By identifying molecular profiles associated with treatment response, this approach has the potential to support faster, more targeted care and improved patient outcomes. Full article: hubs.la/Q04cwHhc0

Castle will release Q1 2026 financial results and host a webcast on Wednesday, May 6 at 4:30 pm ET. Details and login information: hubs.la/Q04c8lx-0 #Q1 #earnings

🏆Looks like it's becoming a tradition (but it never gets old)! We're so excited to have been named a @USATODAY Top Workplace USA for the 5th CONSECUTIVE YEAR! Castle ranked 58th among companies with 500-999 employees. Details: hubs.la/Q04bn7Zm0 #CastleCulture #TopWorkplaces #WeLoveOurPeople❤️

#DidYouKnow? Heartburn and acid reflux could be signs of gastroesophageal reflux disease (#GERD), which left untreated, could progress to Barrett's esophagus (#BE), the only known precursor to esophageal adenocarcinoma (#EAC), a form of esophageal cancer. Learn more about Barrett’s esophagus symptoms, risk factors, and cancer risk. hubs.la/Q049hVJc0 #EsophagealCancerAwarenessMonth #BarrettsEsophagus #TissueCypher

.@CastleBio's #DecisionDx-Melanoma test refines mortality risk within @AJCCancer Cancer Staging System for patients with cutaneous #melanoma, according to research presented at #AAD2026. thedermdigest.com/moving-beyond-…